San Diego-dependent Viking Therapeutics marked itself as a serious competitor inside the weight loss drug market in February right after revealing promising details from a mid-phase demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when offered to be a weekly injection and in March the company unvei